Results of high dose-rate brachytherapy boost before 2D or 3D external beam irradiation for prostate cancer-Reference-Cited by-同舟云学术

Results of high dose-rate brachytherapy boost before 2D or 3D external beam irradiation for prostate cancer

Published:2011-02 Issue:2 Volume:98 Page:169-174
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Neviani Cristiano Beck,Miziara Miguel Abrão,de Andrade Carvalho Heloisa

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference42 articles.

1. INCA. Brasil. Ministério da Saúde. Instituto Nacional do Câncer – INCA, Estimativa 2008. Incidência de câncer no Brasil. Rio de Janeiro: INCA; 2010. http://www.inca.gov.br.

2. Correction: global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000;Shibuya;BMC Cancer,2003

3. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer;Zelefsky;J Urol,2001

4. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial;Pollack;Int J Radiat Oncol Biol Phys,2002

5. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience;Pollack;J Urol,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Penalty weight tuning in high dose rate brachytherapy using multi-objective Bayesian optimization;Physics in Medicine & Biology;2024-05-21

2. Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis;Frontiers in Oncology;2021-11-26

3. Utilization of brachytherapy in Quebec, Canada;Brachytherapy;2021-11

4. High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome;Cancer Reports;2021-06-23

5. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa);Cancer/Radiothérapie;2021-06